Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

COGT

Live52w high -25.3%

Annual Quarterly

Core line items from COGT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: Cogent Biosciences, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-03	Annual 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31
Revenue	$0.00	$7.87M	$7.87M	$7.56M	$7.03M
Operating Income	Not available	$-82.20M	$-70.74M	$-13.54M	$-6.14M
Net Income	Not available	$-74.81M	$-63.47M	$-7.39M	$-6.09M
EPS (Diluted)	$-0.57	Not available	Not available	Not available	Not available
Total Assets	Not available	$250.92M	$139.87M	$31.05M	$38.94M
Total Liabilities	Not available	$16.25M	$23.81M	$11.81M	$13.24M
Cash & Equivalents	Not available	$242.19M	$129.42M	$21.34M	$29.60M
Free Cash Flow OCF − CapEx	Not available	Not available	Not available	Not available	Not available
Shares Outstanding	Not available	32.35M	10.68M	31.16M	30.82M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from COGT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -25.3%

Entity: Cogent Biosciences, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-03	Annual 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31
Revenue	$0.00	$7.87M	$7.87M	$7.56M	$7.03M
Operating Income	Not available	$-82.20M	$-70.74M	$-13.54M	$-6.14M
Net Income	Not available	$-74.81M	$-63.47M	$-7.39M	$-6.09M
EPS (Diluted)	$-0.57	Not available	Not available	Not available	Not available
Total Assets	Not available	$250.92M	$139.87M	$31.05M	$38.94M
Total Liabilities	Not available	$16.25M	$23.81M	$11.81M	$13.24M
Cash & Equivalents	Not available	$242.19M	$129.42M	$21.34M	$29.60M
Free Cash Flow OCF − CapEx	Not available	Not available	Not available	Not available	Not available
Shares Outstanding	Not available	32.35M	10.68M	31.16M	30.82M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.